Vikrant Shekhawat : Oct 10, 2020, 04:31 PM
Washington: U.S. Department of Health and Human Services on Friday signed an agreement with AstraZeneca Plc for development and supply of the company’s COVID-19 antibody treatment, a cocktail of two monoclonal antibodies - similar class of drugs that was administered to President Donald Trump.The agency will provide nearly $486 million to AstraZeneca for two Phase 3 clinical trials as well as a large-scale manufacturing demonstration project and supply of AZD7442 doses in the United States.